# Turbine Simulated Cell Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/turbine-simulated-cell-technologies

- Industry: Biotechnology
- Headquarters: Budapest, Hungary
- Website: www.turbine.ai
- Total disclosed funding: $60M
- Latest round: Series B (Feb 24, 2026)
- Investors on record: 12

## About

Founded in 2015 by Dániel Veres, Kristóf Zsolt Szalay, and Szabolcs Nagy, and based in Budapest, Hungary, Turbine Simulated Cell Technologies Ltd. is a biotechnology company that operates as a developer of an AI-based therapy platform to understand cell simulation and cancer biology. In February 2026, Turbine Simulated Cell Technologies Ltd. raised USD 25 million in series B funding led by Interactive Venture Partners, with participation from Beiersdorf AG, Accel,Mercia Asset Management, Merck Global and Health Innovation Fund.

The firm develops and offers a predictive simulation platform that uses computational models to simulate tumor cell behavior and understand complex disease mechanisms. Their platform combines simulation with machine learning to map interactions among thousands of signaling proteins, characterizing cancer behavior and treatment responses. The platform helps predict drug-like effects, identify ideal patient populations, and uncover novel therapeutic targets. 

The company intends to use the February 2026 funding to expand its virtual biology platform with new assay types, generate proprietary datasets, and support an immunology partnership with a large pharmaceutical company.

## Funding rounds

- Series B, Feb 24, 2026, $25M — Accel, Mercia Asset Management, Merck Global Health Innovation Fund, Beiersdorf AG, Interactive Venture Partners
- Series A, Jun 14, 2023, $6M — MassMutual Ventures
- Series A, Jul 15, 2022, $19M — Accel, Mercia Asset Management, Merck Global Health Innovation Fund, Day One Capital, Delin Ventures, XTX Ventures
- Series A, Nov 12, 2020, $6.7M — Accel, Boston Millennia Partners, Atlantic Labs, O2h Ventures, Delin Ventures, XTX Ventures
- Seed, Sep 16, 2019, $3.3M — Atlantic Labs, O2h Ventures, Delin Ventures
- Seed, Jan 1, 2017 — Atlantic Labs

## Investors

- Atlantic Labs (https://capitalatlas.ai/funds/atlantic-labs) — Seed, Series A
- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Seed, Series A
- Delin Ventures (https://capitalatlas.ai/funds/delin-ventures) — Seed, Series A
- Accel (https://capitalatlas.ai/funds/accel) — Series A, Series B
- Boston Millennia Partners (https://capitalatlas.ai/funds/boston-millennia-partners) — Series A
- XTX Ventures (https://capitalatlas.ai/funds/xtx-ventures) — Series A
- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A, Series B
- Day One Capital (https://capitalatlas.ai/funds/day-one-capital) — Series A
- MassMutual Ventures (https://capitalatlas.ai/funds/massmutual-ventures) — Series A
- Beiersdorf AG — Series B
- Interactive Venture Partners (https://capitalatlas.ai/funds/interactive-venture-partners) — Series B